Operating Income - Viridian Therapeutics Inc (NASDAQ:VRDN) - Alpha Spread

Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 22.5 USD 6.84% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Viridian Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Viridian Therapeutics Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Viridian Therapeutics Inc
NASDAQ:VRDN
Operating Income
-$250.8m
CAGR 3-Years
-24%
CAGR 5-Years
-44%
CAGR 10-Years
-55%
Abbvie Inc
NYSE:ABBV
Operating Income
$16B
CAGR 3-Years
-1%
CAGR 5-Years
5%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.2B
CAGR 3-Years
23%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-14%
CAGR 5-Years
14%
CAGR 10-Years
17%

See Also

What is Viridian Therapeutics Inc's Operating Income?
Operating Income
-250.8m USD

Based on the financial report for Jun 30, 2024, Viridian Therapeutics Inc's Operating Income amounts to -250.8m USD.

What is Viridian Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-55%

Over the last year, the Operating Income growth was -19%. The average annual Operating Income growth rates for Viridian Therapeutics Inc have been -24% over the past three years , -44% over the past five years , and -55% over the past ten years .

Back to Top